Nemorubicin is primarily used in the field of oncology as an anticancer agent. It is particularly investigated for its efficacy in treating hepatocellular carcinoma (HCC), a common type of liver cancer. The drug works by intercalating into DNA, which disrupts the replication process of cancer cells, leading to their destruction. Clinical trials have explored its potential in combination with other therapies to enhance treatment outcomes. Additionally, nemorubicin has shown promise in targeting drug-resistant cancers, making it a valuable candidate in advanced cancer research. Its application is still under study, with ongoing research aimed at optimizing its therapeutic benefits and minimizing side effects.